Literature DB >> 527208

Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

G Peter, H J Hohorst.   

Abstract

Crystalline 4-(SR)-sulfidocyclophosphamides, sulfido derivatives of activated cyclophosphamide (4-hydroxycyclophosphamide), were synthesized by ozonation of cyclophosphamide and reaction of the intermediate 4-hydroxycyclophosphamide with various thiols (HSR). The products were characterized by elemental analysis, 1H NMR and IR spectroscopy, and mass spectrometry. 1H NMR and polarimetric analysis demonstrated that they consist of racemic cis-isomers that are stable in the crystalline state at room temperature. In aqueous solution these derivatives are hydrolyzed to 4-hydroxycyclophosphamide and the corresponding thiol, with half-lives ranging between 4 and 17 min at 37 degrees C and pH 7. The cytotoxicity of 4-(S-ethyl)- and 4-(S-ethanol)-sulfidocyclophosphamide against Yoshida sarcoma ascites cells and the toxicity in rats were found to be practically identical with those of activated cyclophosphamide. A preliminary evaluation of the curative effect after a single IV injection of 4-(S-ethane)- and 4-(S-ethanol)-sulfidocyclophosphamide in rats bearing Yoshida ascites sarcoma or of 4-(S-ethanol)-sulfidocyclophosphamide in nu/nu mice bearing human breast carcinoma xenografts suggested that these sulfido derivatives possess the same oncostatic efficacy as activated cyclophosphamide itself.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 527208     DOI: 10.1007/BF00262420

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.

Authors:  N Brock
Journal:  Cancer Treat Rep       Date:  1976-04

2.  Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry.

Authors:  M Przybylski; H Ringsdorf; G Voelcker; U Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

3.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

4.  Two stable Fenton oxidation products of cyclophosphamide (NSC-26271) as precursors of 4-hydroxycyclophosphamide (NSC-196562) under physiologic conditions.

Authors:  C Benckhuysen; J van der Steen; E J Spanjersberg
Journal:  Cancer Treat Rep       Date:  1976-04

5.  Synthesis, stereochemistry and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and related compounds.

Authors:  A Takamizawa; S Matsumoto; T Iwata; I Makino
Journal:  Chem Pharm Bull (Tokyo)       Date:  1977-08       Impact factor: 1.645

6.  Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.

Authors:  M Przybylski; H Ringsdorf; U Lenssen; G Peter; G Voelcker; T Wagner; H J Hohorst
Journal:  Biomed Mass Spectrom       Date:  1977-08

7.  Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.

Authors:  G Peter; T Wagner; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

8.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

Authors:  J Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

9.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04

10.  [Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].

Authors:  G Voelcker; R Haeglsperger; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

View more
  8 in total

1.  Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells.

Authors:  R H Peters; K Ballard; J E Oatis; D J Jollow; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.

Authors:  L Bielicki; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

3.  Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.

Authors:  U Niemeyer; J Engel; G Scheffler; K Molge; D Sauerbier; W Weigert
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.

Authors:  D S Zaharko; J M Covey; G Hörpel
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  The influence of the protector thiol L-cystein on the toxic and therapeutic responses of stabilized "activated" cyclophosphamide (4-(S-ethanol)-sulfido-cyclophosphamide).

Authors:  G Voelcker; P Laber; H Rockinger; C Wientzek; H J Hohorst
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

6.  A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide).

Authors:  M R Berger; P Bedford; W J Zeller; M Kaufmann
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease.

Authors:  L Bielicki; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

8.  [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Authors:  T Wagner; D Heydrich; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.